Union Bancaire Privee’s BioCryst Pharmaceuticals BCRX Stock Holding History

Union Bancaire Privee’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$77.2K	Buy	+10,000	New	+$90.4K	﹤0.01%	424

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Union Bancaire Privee's BCRX Position: Q2 2026 in Review

Union Bancaire Privee opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 10,000 shares worth $77.2K. The stake represents ﹤0.01% of the portfolio and ranks #424 among its holdings.

318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Union Bancaire Privee held 10,000 shares of BioCryst Pharmaceuticals worth $77.2K as of Q2 2026.
BioCryst Pharmaceuticals was a new Union Bancaire Privee position in Q2 2026.
BioCryst Pharmaceuticals made up ﹤0.01% of Union Bancaire Privee's portfolio in Q2 2026, its #424 holding.
318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Union Bancaire Privee's 13F filing for Q2 2026, filed 16 Jul 2026.